بدائل البحث:
decrease therapeutic » increased therapeutic (توسيع البحث), degrader therapeutics (توسيع البحث), great therapeutic (توسيع البحث)
potent therapeutic » potential therapeutic (توسيع البحث), potential therapeutics (توسيع البحث), novel therapeutic (توسيع البحث)
host resistance » plant resistance (توسيع البحث)
decrease host » decreases short (توسيع البحث)
يعرض 141 - 160 نتائج من 4,352 نتيجة بحث عن '(( ((decrease therapeutic) OR (potent therapeutic)) research ) OR ( decrease host resistance ))', وقت الاستعلام: 0.48s تنقيح النتائج
  1. 141
    Figure S1 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes

    Figure S1 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes حسب Pauline J. van der Watt (15068109)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  2. 142
    Figure S3 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes

    Figure S3 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes حسب Pauline J. van der Watt (15068109)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  3. 143
    Table 1 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia

    Table 1 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia حسب Ziwei Luo (20493559)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  4. 144
    Figure 7 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia

    Figure 7 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia حسب Ziwei Luo (20493559)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  5. 145
    Figure 3 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia

    Figure 3 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia حسب Ziwei Luo (20493559)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  6. 146
    Figure 6 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia

    Figure 6 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia حسب Ziwei Luo (20493559)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  7. 147
    Figure 5 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia

    Figure 5 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia حسب Ziwei Luo (20493559)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  8. 148
    Figure 1 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia

    Figure 1 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia حسب Ziwei Luo (20493559)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  9. 149
    Figure 2 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia

    Figure 2 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia حسب Ziwei Luo (20493559)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  10. 150
    Figure 4 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia

    Figure 4 from Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia حسب Ziwei Luo (20493559)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  11. 151
    Supplementary Excel file-1 from Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties

    Supplementary Excel file-1 from Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties حسب Liangxian Cao (15014480)

    منشور في 2023
    أضف إلى المفضلة
    محفوظ في:
  12. 152
    Supplementary Figure S10 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

    Supplementary Figure S10 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies حسب Di Kang (21364656)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  13. 153
    Supplementary Figure S2 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

    Supplementary Figure S2 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies حسب Di Kang (21364656)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  14. 154
    Supplementary Figure S1 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

    Supplementary Figure S1 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies حسب Di Kang (21364656)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  15. 155
    Supplementary Figure S3 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

    Supplementary Figure S3 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies حسب Di Kang (21364656)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  16. 156
    Supplementary Figure S9 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

    Supplementary Figure S9 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies حسب Di Kang (21364656)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  17. 157
    Supplementary Figure S6 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

    Supplementary Figure S6 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies حسب Di Kang (21364656)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  18. 158
    Supplementary Figure S7 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

    Supplementary Figure S7 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies حسب Di Kang (21364656)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  19. 159
    Supplementary Figure S4 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

    Supplementary Figure S4 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies حسب Di Kang (21364656)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  20. 160
    Supplementary Figure S8 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

    Supplementary Figure S8 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies حسب Di Kang (21364656)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: